key: cord-0860234-hbn9gxqs
authors: Lopian, Miriam; Kashani-Ligumsky, Lior; Czeiger, Shelly; Cohen, Ronnie; Schindler, Yehudit; Lubin, Daniel; Olteanu, Ionna; Neiger, Ran; Lessing, Joseph.B.; Somekh, Eli
title: Safety of Vaginal Delivery in Women Infected with COVID-19
date: 2020-11-02
journal: Pediatr Neonatol
DOI: 10.1016/j.pedneo.2020.10.010
sha: e235880aeede5f4950e7d829763d37d938988d04
doc_id: 860234
cord_uid: hbn9gxqs

Objective There is limited data regarding the safety of vaginal delivery in women infected with COVID-19. Our goal was to assess the safety of vaginal delivery in women infected with COVID-19 and the risk of neonatal infection. Study design This was a single medical center cohort study. Data were collected about the outcome of twenty-one women with laboratory-confirmed COVID-19 infection who delivered between March 23, 2020, and May 8, 2020. Results Twenty-one gravidas were diagnosed with COVID-19 infection. None required admission to the intensive care unit (ICU) and there were no fatalities. Seventeen delivered vaginally and four by caesareans. Apgar scores of all neonates were 9 at 1 minute and 10 at 5 minutes. One neonate was diagnosed with COVID-19 infection 24 hours after birth. Conclusions Vaginal delivery in women infected with COVID-19 is not associated with a significant risk of neonatal infection.

The first cases of the novel coronavirus (COVID-19) infections were diagnosed in 56 PCR confirmation, were delivered in a separate delivery ward or operating room. 79

Patients and attending staff wore masks and protective gear throughout delivery. 80

Immediately after delivery, mothers were separated from their neonates and 81 admitted to the coronavirus ward. Neonates were admitted to the neonatal unit in a 82 separate ward to their mothers. There was no physical contact between the mother 83 and neonate during admission. Women were encouraged to breastfeed via 84 expressed milk with the protection standards described by the CDC guidelines. 5 85

Neonates born to women who tested positive for COVID-19 were tested at 24, 48 86 hours and 5-7 days after birth. Neonates who tested positive for COVID-19 were 87 also tested 14 days after birth. Neonatal follow-up was performed 14 days after 88 discharge. 89

Nasopharyngeal samples from women and neonates were collected using FLOQS 90 swabs (Copan Diagnostics, Murrieta, California, USA) and UTM viral transport 91 medium (Copan Diagnostics, Murrieta, California, USA). Virus inactivation was 92 performed prior to RNA extraction, using the LB buffer (Seegene Inc, Seoul, 93

Republic of Korea). RNA extraction from samples was performed using the EZ1 94

Virus Mini Kit v2.0 by the EZ1 Advanced XL instrument or the QIAcube Connect 95 system (Qiagen, Hilden, Germany), according to manufacturer's instructions. For the 96 EZ1 (400 µl) and the QIAcube (700 µl) each sample was subjected to extraction with 97 an elution volume of 60 µl. Confirmatory testing was performed using a magLEAD kit 98 (Precision System Science Co., Ltd., Chiba, Japan), and 400 µl of each sample was 99 subjected to extraction with an elution volume of 50 µl. An internal control was 100 included in each extraction assay to monitor RNA extraction and real-time Korea). RT -PCR was performed on a CFX96 real-time PCR system (Bio-Rad, 104

Hercules, California, USA). The SARS CoV-2 genes detected by our assay include 105 the RNA-dependent RNA polymerase (RdRp), envelope (E), and nucleocapsid 106 (N) genes.This assay was conducted according to the kit manufacturer's instructions. 107

The limit of detection for the 'E' and 'N' gene was 4,167 copies/mL and for the 108 'RdRp' gene, 1,250 copies/mL. The clinical sensitivity was 20/20 for the 'N' and 'E' 109 genes and 19/20 for the 'RdRp' gene. A non-template (water) control was included in 110 every RT -PCR run. 111

Symptomatic medical staff and those exposed to infected patients without 112 appropriate protection as described by the CDC guidelines 5 were tested for COVID-113

19. No member of the medical staff tested positive for COVID-19. 114

The data was analyzed using the analyzer module of the software and results were 115 delivered at 32 weeks after having premature rupture of membranes and developing 128 spontaneous labor. On admission, 10 patients were asymptomatic (Table 1) . Two 129 women received treatment with azithromycin (500mg once a day for 5 days) and 130 hydroxychloroquine (200mg twice a day for 10 days) and one patient received 131 azithromycin only, per the recommendations of infectious disease physicians, based 132 on their clinical presentation. No woman required oxygen support, none were 133 admitted to the intensive care unit and none required intubation. There were no 134

Seventeen women delivered vaginally, two of them by vacuum extraction due to non-136 reassuring fetal status. Four women were delivered by caesarean section due to 137 three previous caesareans, breech position, a non-reassuring fetal status and 138 suspected uterine rupture in a woman with a history of two previous caesareans 139 (Table 1) . Apgar scores of all neonates were 9 at 1 minute and 10 at 5 minutes. 140

Average birth weight was 3353 grams (range 1920-4070). All birthweights were 141 appropriate for gestational age (Table 1) . One neonate (born to patient 1) was 142 diagnosed with COVID-19 infection by PCR analysis of nasopharyngeal swabs taken 143 at 24 and 48 hours of age and twenty neonates had negative PCR swabs at 24 and 144 48 hours of age as well as 5-7 days of age. The mother of this baby (patient 1) 145 presented at 37 weeks' gestation with a persistent cough and malaise. Her 146 temperature on admission was 38.4°C. Her oxygen saturation was normal, she was 147 hemodynamically stable and not dyspneic. There was no evidence of leukocytosis, The patient was tested for COVID -19, and once this infection was diagnosed, she 153 was isolated in the coronavirus ward. She continued to have a fever, including on the 154 day of delivery. On hospital day three, her membranes ruptured. She underwent an 155 induction of labor by oxytocin and delivered six hours later by vacuum extraction due 156 to a non-reassuring fetal status. 157

A male neonate weighing 2770 grams was delivered with Apgar scores of 9 and10 at 158 1 and 5 minutes, respectively. Arterial cord blood gas analysis showed normal pH 159 and lactate. Vital parameters were normal throughout his admission and he did not 160 require respiratory support or an admission to the NICU. Nasopharyngeal swabs 161

were first collected at 24 and at 48 hours of life: they were tested with RT-PCR and 162

were both positive for the SARS-CoV-2 genes. Feeding was provided using 163 expressed milk with the protection standards described by the CDC guidelines. 5 The 164

neonate did not receive antiviral medications or any other specific treatment and was 165 discharged from the hospital after 7 days. He tested negative for COVID-19 at 7,14 166

and 17 days of life. An examination at 14 days of life was normal. None of the staff 167 members who were in contact with the mother and the neonate were found to be 168 positive for COVID-19. Although an external source for infection is unlikely since strict infection control 217 measures were implemented during and after delivery, it cannot be ruled out. 218

Another possibility is an intrapartum respiratory spread: the mother wore a face 219 mask during delivery, but at times she required the use of an oxygen mask due to 220 non-reassuring fetal status. Delivery was in accordance with droplet precautions, but 221 it was not in an airborne infection isolation room (AIIR). Since the neonate was in this 222 room for several minutes after birth, it is possible that the neonate was infected fetal growth. In our study, PCR testing for SARS-CoV-2 was only performed on days 265 1, 2 and day 5-7 postpartum. Whilst the average incubation period for SARS CoV-2 266 is around 6 days, it can extend to 14 days. 34 Therefore, we cannot exclude the 267 possibility that neonates that had initially tested negative for SARS CoV-2 did not 268 seroconvert within the 14-day incubation period. That said, all exposed neonates 

Pregnancy 325 and perinatal outcomes of women with severe acute respiratory 326 syndrome

Middle East Respiratory Syndrome 329

MERS-CoV) infection during pregnancy: Report of two cases & 330 review of the literature

Infection With SARS-CoV-2 in 33 Neonates Born to Mothers With

de infección neonatal por SARS-CoV-2 en España

Coronavirus Disease in China

Transplacental transmission of SARS-CoV-2 infection

Possible Vertical 346 Transmission of SARS-CoV-2 From an Infected Mother to Her Newborn

J o u r n a l P r e -p r o o f COVID-19, coronavirus disease 2019; CRP, C-reactive protein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NA, not applicable; VE, vacuum extraction; SVD, spontaneous vaginal delivery; CS, cesarean section. 1 Lymphocyte count of <1.1x10 3 cells/µL 2 CRP level of >10mg/L 3 ALT level of >45U/L or AST level of >35U/L 4 For patients who were diagnosed with COVID-19 two weeks before delivery, repeat test for SARS-CoV-2 was performed on admission to delivery and was found still positive. 5 leukocyte count of >14x10 3 cells/µL